Wells Fargo & Company Neuro Bo Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.4 - $0.9 $2 - $5	6 Added 1.71%	356 $0
Q4 2021 Feb 14, 2022	BUY	$1.22 - $2.5 $32 - $67	27 Added 8.36%	350 $0
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.52 $8 - $13	3 Added 0.94%	323 $1,000
Q2 2021 Aug 16, 2021	SELL	$2.74 - $4.63 $36,831 - $62,236	-13,442 Reduced 97.67%	320 $1,000
Q1 2021 May 13, 2021	SELL	$3.93 - $6.68 $14,934 - $25,384	-3,800 Reduced 21.64%	13,762 $61,000
Q4 2020 Feb 09, 2021	BUY	$5.02 - $6.59 $81,449 - $106,922	16,225 Added 1213.54%	17,562 $92,000
Q3 2020 Nov 05, 2020	SELL	$5.41 - $8.67 $4,603 - $7,378	-851 Reduced 38.89%	1,337 $7,000
Q2 2020 Aug 13, 2020	BUY	$8.05 - $29.44 $17,468 - $63,884	2,170 Added 12055.56%	2,188 $18,000
Q1 2020 May 14, 2020	BUY	$7.24 - $30.0 $130 - $540	18 New	18 $0

Ticker NRBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 888,693
Market Cap $2.4M
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the tr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.